185 related articles for article (PubMed ID: 2412021)
1. Why use angiotensin converting enzyme inhibitors to lower blood pressure?
MacGregor GA; Markandu ND; Smith SJ; Sagnella GA
J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S92-7. PubMed ID: 2412021
[TBL] [Abstract][Full Text] [Related]
2. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
Atkinson AB; Morton JJ; Brown JJ; Davies DL; Fraser R; Kelly P; Leckie B; Lever AF; Robertson JI
Br Heart J; 1980 Sep; 44(3):290-6. PubMed ID: 7000102
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibition reveals an important role for the renin system in the control of normal and high blood pressure in man.
MacGregor GA; Markandu ND; Smith SJ; Sagnella GA; Morton JJ
Clin Exp Hypertens A; 1983; 5(7-8):1367-80. PubMed ID: 6315274
[TBL] [Abstract][Full Text] [Related]
4. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
5. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
6. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
7. The renin--angiotensin--aldosterone system in the maintenance of blood pressure, aldosterone secretion and sodium balance in normotensive subjects.
MacGregor GA; Markandu ND; Roulston JE; Jones JC; Morton JJ
Clin Sci (Lond); 1980 Dec; 59 Suppl 6():95s-99s. PubMed ID: 7004744
[TBL] [Abstract][Full Text] [Related]
8. Renin in essential hypertension.
Atlas SA; Case DB
Clin Endocrinol Metab; 1981 Nov; 10(3):537-75. PubMed ID: 6124330
[No Abstract] [Full Text] [Related]
9. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers.
Shepherd AN; Campbell BC; Reid JL
J Cardiovasc Pharmacol; 1982; 4(3):381-7. PubMed ID: 6177933
[TBL] [Abstract][Full Text] [Related]
10. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients.
Ogihara T; Maruyama A; Hata T; Mikami H; Nakamaru M; Naka T; Ohde H; Kumahara Y
Clin Pharmacol Ther; 1981 Sep; 30(3):328-35. PubMed ID: 6268347
[TBL] [Abstract][Full Text] [Related]
11. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
[TBL] [Abstract][Full Text] [Related]
12. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
Jensen J; Henik RA; Brownfield M; Armstrong J
Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
[TBL] [Abstract][Full Text] [Related]
13. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
Iimura O; Shimamoto K
Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
[TBL] [Abstract][Full Text] [Related]
14. Captopril in the long-term treatment of essential hypertension: changes in the renin-angiotensin-aldosterone system.
Riegger GA; Steilner H; Hayduk K; Liebau G
Am J Cardiol; 1982 Apr; 49(6):1555-7. PubMed ID: 6803566
[TBL] [Abstract][Full Text] [Related]
15. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
Shimosawa T
Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
[TBL] [Abstract][Full Text] [Related]
16. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats.
Bolterman RJ; Manriquez MC; Ortiz Ruiz MC; Juncos LA; Romero JC
Hypertension; 2005 Oct; 46(4):943-7. PubMed ID: 16087785
[TBL] [Abstract][Full Text] [Related]
17. Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin converting enzyme.
Weber MA; Drayer JI; Priest RT; Chen TC
Am J Nephrol; 1982; 2(1):6-11. PubMed ID: 6295161
[TBL] [Abstract][Full Text] [Related]
18. The renin-angiotensin system during converting enzyme inhibition with captopril in patients with severe treatment-resistant hypertension.
Rasmussen S; Damkjaer Nielsen M; Ibsen H; Leth A; Giese J
Eur J Clin Invest; 1984 Feb; 14(1):30-6. PubMed ID: 6321195
[TBL] [Abstract][Full Text] [Related]
19. Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects.
Schlaich MP; Klingbeil A; Hilgers K; Schobel HP; Schmieder RE
Am Heart J; 1999 Nov; 138(5 Pt 1):810-7. PubMed ID: 10539810
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of captopril (Tensiomin) in patients with hypertension.
Török E; Bíró V; Wagner M; Kósa E; Podmaniczky M; Cseh K
Acta Physiol Hung; 1988; 72 Suppl():51-65. PubMed ID: 2908092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
